Form 8-K - Current report:
SEC Accession No. 0001437749-24-026397
Filing Date
2024-08-13
Accepted
2024-08-13 16:17:16
Documents
16
Period of Report
2024-08-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K zvra20240520_8k.htm   iXBRL 8-K 33306
2 EXHIBIT 99.1 ex_676970.htm EX-99.1 197557
7 zvralogo.jpg GRAPHIC 6458
  Complete submission text file 0001437749-24-026397.txt   392691

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA zvra-20240813.xsd EX-101.SCH 3409
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE zvra-20240813_def.xml EX-101.DEF 11424
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE zvra-20240813_lab.xml EX-101.LAB 15310
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE zvra-20240813_pre.xml EX-101.PRE 11584
18 EXTRACTED XBRL INSTANCE DOCUMENT zvra20240520_8k_htm.xml XML 2837
Mailing Address 1180 CELEBRATION BOULEVARD, SUITE 103 CELEBRATION FL 34747
Business Address 1180 CELEBRATION BOULEVARD, SUITE 103 CELEBRATION FL 34747 (321) 939-3416
ZEVRA THERAPEUTICS, INC. (Filer) CIK: 0001434647 (see all company filings)

EIN.: 205894398 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36913 | Film No.: 241201728
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)